To view enhanced content for this article go to http://www.medengine.com/Redeem/14E6F0601466A5CC.
The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain.
Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs.
A total of 188 individuals participated in the study. For all participants, when choosing treatments, the best rated characteristics were greater efficacy, greater safety, treatment adaptation to patients’ individual requirements and the rapid reincorporation of patients to their daily activities. There were important differences among participants in their opinion about survival, QoL and cost. In general, oncologists, patients, and the general population gave greater value to gains in QoL than healthcare policy makers. Compared to other participants healthcare policy makers gave greater importance to the economic impact related to oncology treatments.
Gains in QoL, survival, safety, cost and innovation are perceived differently by different groups of stakeholders. It is recommended to consider the perspective of different stakeholders in the assessment of a new cancer drugs to obtain more informed decisions when deciding on the most appropriate treatment to use.
Eli Lilly & Co, Madrid (Spain).
National Cancer Institute, Surveillance Epidemiology and End Results. Available at http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. Accessed Nov 2014.
Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2014; 32(2):129–60. Available at http://jco.ascopubs.org/content/32/2/129.full.pdf+html. Accessed Nov 2014.
Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935–43. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538397/pdf/main.pdf. Accessed 4 March 2015.
Sorenson C, Drummond M, Kanavos P. Ensuring value for money in healthcare: the role of health technology assessment in the European Union. European observatory on health systems and polices. Observatory studies series No 11. Copenhagen: WHO; 2008. Available at http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf. Accessed 15 Dec 2015.
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–73. CrossRefPubMed
Marshall B, Cardon P, Poddar A, Fontenot R. Does sample size matter in qualitative research? A review of qualitative interviews in is research. J Comput Inform Syst. 2013;54(1):11–22.
National Cancer Institute. Available at http://www.cancer.gov/about-cancer/treatment/side-effects. Accessed Sept 2014.
Dilla T, Lizan L, Paz S, Garrido P, Avendaño C, Cruz-Hernández JJ, Espinosa J, Sacristán JA. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adher. 2015;18(10):1–7.
Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, et al. Which is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive heart failure interventions. Value Health. 2013;16(5):842–7. CrossRefPubMed
Herikson N, Tuzzio L, Loggers ET, Miyoshi J, Buist D. Patient and oncologist discussions about cancer care costs. Support Care Cancer. 2014;22(4):961–7. CrossRef
- Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology
José A. Sacristán
Juan J. Cruz-Hernández
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II